Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,netBorrowings,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,GERN,201162000.0,318568000,5971000,,-27824000,,-27824000,7478000,-15005000,-28454000,-28454000,,-743000,,,,0,137000,28591000,15142000,630000,,-27824000,-27824000,1384262000.0,57446000.0,201162000.0,258608000.0,318000.0,363000.0,-1183453000.0,35000.0,4272000.0,31537000.0,28552000.0,35000.0,5783000.0,215264000.0,33289000.0,179490000.0,759000.0,24222000.0,4459000.0,38093000.0,0.0,38083000.0,16263000.0,-6272000.0,16263000.0,21612000.0,-32734000.0,180000.0,1002000.0,-10000.0,,,186712000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,Geron Corporation,-0.01673902,477268160,-4.1714287,2.3101265,15,America/New_York,EDT,-14400000,False,False,POST,0,4,1.46,1630526402,0.00999999,1.45,1.47,1.43,1302838,NMS,us_market,0.0,1630533440,1.46,0.0,0.68965447,1.43 - 1.47,1.45,1.45,1.47,388,400,finmb_215864,NasdaqGS,Geron Corporation,USD,8469148,2084333,0.26,0.21666665,1.2 - 2.36,-0.89999986,-0.38135588,1.2,2.36,1620676800,1620676800,1620676800,-0.288,-0.35,-0.36,-4.0555553,0.632,1.2755556,0.18444443,0.14459929,1.484855,-0.024855018,1.11,,,2.36,1.2,1.2756,1.4849,8.47M,2.08M,318.57M,,287.9M,0.17%,46.28%,26.84M,16.38,8.48%,8.42%,25.95M,,,,,,0.00%,,,1058:1000,"Jul 21, 2014","Dec 30, 2020","Mar 30, 2021",0.00%,"-26,182.54%",-27.55%,-54.10%,338k,0.00,163.50%,-49.8M,-88.32M,-87.09M,-0.2880,,211.03M,0.66,29.78M,14.80,7.54,0.63,-73.19M,-38.67M,Value,94404,Healthcare,53,7,4,"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.",Foster City,650 473 7700,CA,8,1609372800,1622505600,3,United States,http://www.geron.com,86400,6,919 East Hillsdale Boulevard,650 473 7700,Biotechnology,Suite 250
t-1,GERN,210947000.0,318568000,-12580000,,-23787000,,-23787000,8524000,-27322000,-23266000,-23266000,,-657000,,,,0,50000,23316000,27372000,-521000,,-23787000,-23787000,1366188000.0,59781000.0,210947000.0,270728000.0,310000.0,363000.0,-1155629000.0,78000.0,1170000.0,9925000.0,30940000.0,78000.0,5953000.0,199857000.0,63748000.0,186350000.0,722000.0,24042000.0,6919000.0,-21825000.0,5731000.0,-21836000.0,-581000.0,2746000.0,111000.0,-35031000.0,-12614000.0,179000.0,2338000.0,-11000.0,-692000.0,,168917000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,Geron Corporation,-0.01673902,477268160,-4.1714287,2.3101265,15,America/New_York,EDT,-14400000,False,False,POST,0,4,1.46,1630526402,0.00999999,1.45,1.47,1.43,1302838,NMS,us_market,0.0,1630533440,1.46,0.0,0.68965447,1.43 - 1.47,1.45,1.45,1.47,388,400,finmb_215864,NasdaqGS,Geron Corporation,USD,8469148,2084333,0.26,0.21666665,1.2 - 2.36,-0.89999986,-0.38135588,1.2,2.36,1620676800,1620676800,1620676800,-0.288,-0.35,-0.36,-4.0555553,0.632,1.2755556,0.18444443,0.14459929,1.484855,-0.024855018,1.11,,,2.36,1.2,1.2756,1.4849,8.47M,2.08M,318.57M,,287.9M,0.17%,46.28%,26.84M,16.38,8.48%,8.42%,25.95M,,,,,,0.00%,,,1058:1000,"Jul 21, 2014","Dec 30, 2020","Mar 30, 2021",0.00%,"-26,182.54%",-27.55%,-54.10%,338k,0.00,163.50%,-49.8M,-88.32M,-87.09M,-0.2880,,211.03M,0.66,29.78M,14.80,7.54,0.63,-73.19M,-38.67M,Value,94404,Healthcare,53,7,4,"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.",Foster City,650 473 7700,CA,8,1609372800,1622505600,3,United States,http://www.geron.com,86400,6,919 East Hillsdale Boulevard,650 473 7700,Biotechnology,Suite 250
t-2,GERN,232832000.0,318568000,4423000,,-19651000,,-19651000,6510000,-9082000,-20015000,-20015000,,-49000,,,,0,108000,20123000,9190000,364000,,-19651000,-19651000,1364194000.0,52961000.0,232832000.0,285793000.0,310000.0,363000.0,-1131842000.0,170000.0,1665000.0,44956000.0,24154000.0,170000.0,6114000.0,231861000.0,46153000.0,182667000.0,989000.0,23885000.0,3739000.0,13568000.0,0.0,13564000.0,23976000.0,1931000.0,111000.0,22091000.0,-15449000.0,116000.0,2155000.0,-4000.0,24555000.0,-579000.0,207707000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,Geron Corporation,-0.01673902,477268160,-4.1714287,2.3101265,15,America/New_York,EDT,-14400000,False,False,POST,0,4,1.46,1630526402,0.00999999,1.45,1.47,1.43,1302838,NMS,us_market,0.0,1630533440,1.46,0.0,0.68965447,1.43 - 1.47,1.45,1.45,1.47,388,400,finmb_215864,NasdaqGS,Geron Corporation,USD,8469148,2084333,0.26,0.21666665,1.2 - 2.36,-0.89999986,-0.38135588,1.2,2.36,1620676800,1620676800,1620676800,-0.288,-0.35,-0.36,-4.0555553,0.632,1.2755556,0.18444443,0.14459929,1.484855,-0.024855018,1.11,,,2.36,1.2,1.2756,1.4849,8.47M,2.08M,318.57M,,287.9M,0.17%,46.28%,26.84M,16.38,8.48%,8.42%,25.95M,,,,,,0.00%,,,1058:1000,"Jul 21, 2014","Dec 30, 2020","Mar 30, 2021",0.00%,"-26,182.54%",-27.55%,-54.10%,338k,0.00,163.50%,-49.8M,-88.32M,-87.09M,-0.2880,,211.03M,0.66,29.78M,14.80,7.54,0.63,-73.19M,-38.67M,Value,94404,Healthcare,53,7,4,"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.",Foster City,650 473 7700,CA,8,1609372800,1622505600,3,United States,http://www.geron.com,86400,6,919 East Hillsdale Boulevard,650 473 7700,Biotechnology,Suite 250
t-3,GERN,250681000.0,318568000,3987000,,-15824000,,-15824000,5960000,-6815000,-16762000,-16762000,,-49000,,,,0,43000,16805000,6858000,938000,,-15824000,-15824000,1362373000.0,24133000.0,250681000.0,274814000.0,310000.0,363000.0,-1112191000.0,189000.0,954000.0,22865000.0,19142000.0,189000.0,6226000.0,220743000.0,46891000.0,195881000.0,822000.0,,3797000.0,-129011000.0,0.0,-129206000.0,144265000.0,1765000.0,144265000.0,2664000.0,-12395000.0,369000.0,1295000.0,-195000.0,24555000.0,-579000.0,201601000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,Geron Corporation,-0.01673902,477268160,-4.1714287,2.3101265,15,America/New_York,EDT,-14400000,False,False,POST,0,4,1.46,1630526402,0.00999999,1.45,1.47,1.43,1302838,NMS,us_market,0.0,1630533440,1.46,0.0,0.68965447,1.43 - 1.47,1.45,1.45,1.47,388,400,finmb_215864,NasdaqGS,Geron Corporation,USD,8469148,2084333,0.26,0.21666665,1.2 - 2.36,-0.89999986,-0.38135588,1.2,2.36,1620676800,1620676800,1620676800,-0.288,-0.35,-0.36,-4.0555553,0.632,1.2755556,0.18444443,0.14459929,1.484855,-0.024855018,1.11,,,2.36,1.2,1.2756,1.4849,8.47M,2.08M,318.57M,,287.9M,0.17%,46.28%,26.84M,16.38,8.48%,8.42%,25.95M,,,,,,0.00%,,,1058:1000,"Jul 21, 2014","Dec 30, 2020","Mar 30, 2021",0.00%,"-26,182.54%",-27.55%,-54.10%,338k,0.00,163.50%,-49.8M,-88.32M,-87.09M,-0.2880,,211.03M,0.66,29.78M,14.80,7.54,0.63,-73.19M,-38.67M,Value,94404,Healthcare,53,7,4,"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.",Foster City,650 473 7700,CA,8,1609372800,1622505600,3,United States,http://www.geron.com,86400,6,919 East Hillsdale Boulevard,650 473 7700,Biotechnology,Suite 250
